



**Workshop on implementation of WHO
guidelines of biotherapeutics including
biosimilars in Russian speaking countries**

**Copenhagen, Denmark
05 – 07 July 2017**

31 May 2017

Original: English

Provisional programme

Wednesday, 5 July 2017

Session 1

08:30 - 09:00

09:00 - 09:15

09:15 - 09:35

09:35 - 09:50

Welcome and Introduction

Registration – Participants

Opening remarks

Self-introduction

Announce the results of assessing DOI; Housekeeping
announcement – WHO EURO

Session 2

09:50 - 10:15

10:15 - 10:30

Background and Objectives

WHO activities/updates in the area of biotherapeutics – Dr H. Kang
(WHO HQ)

Background, objectives and expected outcomes of the meeting –
WHO EURO

10:30 - 11:00

Coffee break

Session 3

11:00 - 11:30

11:30 - 12:00

12:00 - 12:30

12:30 - 13:00

**Regulatory expectations for biotherapeutics including
biosimilars**

Quality aspect - TBD

Clinical aspect – TBD

Immunogenicity assessment – Dr R. Thorpe (WHO consultant)

Discussion

13:00 - 14:00

Lunch break

Session 4

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

**Specific considerations and challenges in development of
biosimilars**

Issues related to reference products – Industry representative

Extrapolation of indication – Industry representative

Discussion

15:30 – 16:00

Coffee break

Session 5	Guiding principles for regulatory assessment of bioterapeutics
16:00 - 17:00	Key principles in WHO guidelines & Review examples – Dr E. Griffiths (WHO consultant)
17:00 - 17:30	Discussion

Thursday, 6 July 2017

Session 6	Analytical comparability assessment of biosimilars
09:00 - 09:30	Introduction and summary of IPRF material for regulatory reviewers – Dr H. Kang (WHO HQ)
09:30 - 10:30	Experience sharing from pre-workshop self-study – Representatives (4 countries)
10:30 - 11:00	<i>Coffee break</i>
11:00 - 11:30	Evaluation and interpretation of quality comparability exercise results (EPO case) – Industry representative
11:30 - 12:00	Discussion
12:00 - 13:00	<i>Lunch break</i>
Session 7	Case study
13:00 - 13:30	The role and influence of the quality assessment (EPO) – TBD
13:30 - 15:30	Work in groups
15:30 - 16:00	<i>Coffee break</i>
16:00 - 17:00	Feedback from groups – Leader of each group
17:00 - 18:00	Overall discussion & Conclusion
18:00	Close of open meeting

Friday, 7 July 2017 Closed sessions (regulators and participants without conflict of interest)

Session 8	Report from countries
09:00 - 10:30	Country situation (regulatory framework, approval process, recent updates and challenges), Implementation of WHO guidelines (practical uses or plan for implementation), and Proposal to WHO – A representative from each country
10:30 - 11:00	<i>Coffee break</i>

Session 9

11:00 - 12:00

Conclusions and next steps

Discussion & Lessons learnt

12:00 – 13:00

Summary of the workshop: Conclusions and next steps

13:00

Close of meeting

